Your browser doesn't support javascript.
COVID-19 in hospitalised patients in Spain: a cohort study in Madrid.
Rodriguez-Gonzalez, Carmen Guadalupe; Chamorro-de-Vega, Esther; Valerio, Maricela; Amor-Garcia, Miguel Angel; Tejerina, Francisco; Sancho-Gonzalez, Milagros; Narrillos-Moraza, Alvaro; Gimenez-Manzorro, Alvaro; Manrique-Rodriguez, Silvia; Machado, Marina; Olmedo, Maria; Escudero-Vilaplana, Vicente; Villanueva-Bueno, Cristina; Torroba-Sanz, Beatriz; Melgarejo-Ortuño, Alejandra; Vicente-Valor, Juan; Herranz, Ana; Bouza, Emilio; Muñoz, Patricia; Sanjurjo, Maria.
  • Rodriguez-Gonzalez CG; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. Electronic address: crgonzalez@salud.madrid.org.
  • Chamorro-de-Vega E; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Valerio M; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Amor-Garcia MA; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Tejerina F; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Sancho-Gonzalez M; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Intensive Care Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Narrillos-Moraza A; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Gimenez-Manzorro A; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Manrique-Rodriguez S; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Machado M; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Olmedo M; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Escudero-Vilaplana V; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Villanueva-Bueno C; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Torroba-Sanz B; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Melgarejo-Ortuño A; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Vicente-Valor J; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Herranz A; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Bouza E; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; CIBERES, CIBER Enfermedades Respiratorias, Madrid, Spain; Departamento de Medicina, Facultad de Medicina, Un
  • Muñoz P; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; CIBERES, CIBER Enfermedades Respiratorias, Madrid, Spain; Departamento de Medicina, Facultad de Medicina, Un
  • Sanjurjo M; Pharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Int J Antimicrob Agents ; 57(2): 106249, 2021 Feb.
Article in English | MEDLINE | ID: covidwho-996948
ABSTRACT
Few large series describe the clinical characteristics, outcomes and costs of COVID-19 in Western countries. This cohort reports the first 1255 adult cases receiving anti-COVID-19 treatment at a Spanish hospital (1-24 March 2020). Treatment costs were calculated. A logistic regression model was used to explore risk factors on admission associated with ARDS. A bivariate Cox proportional hazard ratio (HR) model was employed to determine the HR between individual factors and death. We included 1255 patients (median age 65 years; 57.8% male), of which 92.3% required hospitalisation. The prevalence of hypertension, cardiovascular disease and diabetes mellitus (DM) was 45.1%, 31.4% and 19.9%, respectively. Lymphocytopenia (54.8%), elevated alanine aminotransferase (33.0%) and elevated lactate dehydrogenase (58.5%) were frequent. Overall, 36.7% of patients developed ARDS, 10.0% were admitted to an ICU and 21.3% died. The most frequent antiviral combinations were lopinavir/ritonavir plus hydroxychloroquine (44.2%), followed by triple therapy with interferon beta-1b (32.7%). Corticosteroids and tocilizumab were used in 25.3% and 12.9% of patients, respectively. Total cost of anti-COVID-19 agents was €511 825 (€408/patient). By multivariate analysis, risk factors associated with ARDS included older age, obesity, DM, severe hypoxaemia, lymphocytopenia, increased creatine kinase and increased C-reactive protein. In multivariate Cox model, older age (HR 1.07, 95% CI 1.06-1.09), cardiovascular disease (HR 1.34, 95% CI 1.01-1.79), DM (HR 1.45, 95% CI 1.09-1.92), severe hypoxaemia (HR 2.01, 95% CI 1.49-2.72), lymphocytopenia (HR 1.62, 95% CI 1.20-2.20) and increased C-reactive protein (HR 1.04, 95% CI 1.02-1.06) were risk factors for mortality.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / COVID-19 Drug Treatment Type of study: Cohort study / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Int J Antimicrob Agents Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / COVID-19 Drug Treatment Type of study: Cohort study / Observational study / Prognostic study Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: English Journal: Int J Antimicrob Agents Year: 2021 Document Type: Article